Don’t miss the latest developments in business and finance.

Granules receives USFDA approval for Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets

Image
Capital Market
Last Updated : Aug 27 2022 | 12:31 PM IST
Granules India announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Guaifenesin and Pseudoephedrine Hydrochloride Extended-Release (ER) Tablets, 600 mg/60 mg and 1200 mg/120 mg (OTC).

It is bioequivalent to the reference listed drug product, Mucinex D Extended-Release Tablets, 600 mg/60 mg and 1200 mg/120 mg, of RB Health (US) LLC.

Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets are used to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive; temporarily relieve nasal congestion due to common cold, hay fever, upper respiratory allergies; temporarily restores freer breathing through the nose; promotes nasal and/or sinus drainage; and temporarily relieves sinus congestion and pressure.

The Mucinex D brand and store brands had combined U.S. sales of approximately $71 million MAT for the most recent twelve months.

Powered by Capital Market - Live News

Also Read

First Published: Aug 27 2022 | 12:14 PM IST

Next Story